What is Edwards Lifesciences's surgical — net sales?

Edwards Lifesciences (EW) reported surgical — net sales of $276.2M in Q1 2026.

What does surgical — net sales mean?

This metric represents the total revenue generated from the sale of surgical structural heart products, including tissue heart valves and related surgical repair devices. It reflects the company's performance in the traditional open-heart surgery market, which serves as a foundational revenue stream alongside newer transcatheter technologies. This segment is a key indicator of market share stability and adoption rates for established surgical interventions.

Edwards Lifesciences EW Surgical — Net Sales

Other product segments

Transcatheter Aortic Valve Replacement

$1.2B+14.4%

Transcatheter Mitral and Tricuspid Therapies

$175.1M+52.0%

Similar metrics at other companies

ENOVSurgical — Net Sales

$317.13M+10.8%

MDXGSurgical — Net Sales

$36.37M+13.2%

TFX

TFXSurgical — Net revenues

$106.79M+12.4%

MDLNSurgical Solutions — Net Sales

$1.55B+7.4%

BVSSurgical Solutions — Total Net Sales

$48.03M+6.2%

CNMDGeneral Surgery — Net Sales

$169.38M-7.4%

Other financials

Income statement

See full

Revenue$1.6B+16.7%

Gross profit$1.3B+15.7%

Operating income$477.6M+21.0%

Net income$380.7M+6.3%

EPS (diluted)$0.66+8.2%

Balance sheet

See full

Cash & equivalents$2.4B-22.3%

Total debt$702.9M+0.5%

Total equity$10.3B+2.0%

Total assets$13.3B+2.3%

Cash flow

See full

Operating cash flow$43.8M-84.4%

CapEx$64.9M+15.9%

Free cash flow-$21.1M-109%

Valuation

See full

Market cap$51.66B+19.3%

Enterprise value$49.92B+22.2%

P/E47.1×+36.8×

P/S8.2×+0.4×

Profitability

See full

Gross margin77.9%-1.6pp

Operating margin21.4%-4.4pp

Net margin17.4%-58.3pp

FCF margin17.3%—

Returns & leverage

See full

Return on equity10.7%-37.8pp

Debt / equity0.1×0.0×

Current ratio4.4×0.0×

Where this comes from

Reported directly by Edwards Lifesciences in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Edwards Lifesciences’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Edwards Lifesciences's surgical — net sales.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Edwards Lifesciences's surgical — net sales?: Edwards Lifesciences (EW) reported surgical — net sales of $276.2M in Q1 2026.
What does surgical — net sales mean?: This metric represents the total revenue generated from the sale of surgical structural heart products, including tissue heart valves and related surgical repair devices. It reflects the company's performance in the traditional open-heart surgery market, which serves as a foundational revenue stream alongside newer transcatheter technologies. This segment is a key indicator of market share stability and adoption rates for established surgical interventions.